Blue Skies: Merck Looks For Chronic Pain Candidates In Australia
This article was originally published in PharmAsia News
Executive Summary
In a deal described as “out of the blue” by Australian biotech Bionomics, Merck has acquired an option to license a small molecule for up to $172 million in fees and milestones as part of a two-year research program focused on chronic pain treatments.